Though prostate tumors from HOXB13 G84E carriers are frequently low grade and indolent, these results may have therapeutic implications for the rare carriers who develop metastatic disease and who may benefit from FASN inhibitors. This evidence concerns the gene FASN and prostate neoplasm.